Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule approaches. One modality that has shown potential when employed against these targets is cyclic peptides.
In this talk, Dr. Gardner will explore how the Dianthus instrument with Spectral Shift technology has been integrated into Curve Therapeutics' screening cascade to validate cyclic peptide hits. He will present results with a focus on assay development, affinity screening, data processing, and a comparison of the results he obtained from the two biophysical technologies available in Dianthus.
